Microstent implantation in Schlemm’s canal reduces early postoperative IOP following cataract surgery in patients with mild or moderate glaucoma, according to findings from the HORIZON study of the Hydrus microstent, according to a Reuters report.
“This study suggests that the use of Hydrus microstent may protect against very high post-operative IOPs (that can result in morbidity in already vulnerable glaucomatous eyes),” Dr. Nazlee Zebardast of Massachusetts Eye and Ear Infirmary, Harvard Medical School, in Boston, told Reuters Health by email. “However, whether this justifies a permanent implant is unclear.”
Acute post-cataract surgery IOP elevation occurs more frequently in glaucoma patients and can result in optic-nerve damage. Oral carbonic-anhydrase inhibitors can reduce this risk in some patients, but they cannot be used safely in all patients.